| Bid | 3.33 |
| Market Cap | 273.76M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.15 |
| PE Ratio (ttm) | 24.47 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 4.59 |
| Volume | 1,215,258 |
| Avg. Volume (20D) | 776,860 |
| Open | 3.72 |
| Previous Close | 3.70 |
| Day's Range | 3.61 - 3.77 |
| 52-Week Range | 3.52 - 8.33 |
| Beta | undefined |
About OSUR
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test...
Analyst Forecast
According to 2 analyst ratings, the average rating for OSUR stock is "Hold." The 12-month stock price forecast is $5.5, which is an increase of 49.86% from the latest price.
Next Earnings Release
Analysts project revenue of $38.54M, reflecting a -49.21% YoY shrinking and earnings per share of -0.06, making a -127.27% decrease YoY.
1 month ago · seekingalpha.com
OraSure Technologies: Discounted Assets With An Attractive Free Call OptionOraSure Technologies is undervalued, trading below its net current asset value, offering a compelling risk-reward scenario with limited downside risk. The company has a robust balance sheet with no lo...
